Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:ATCCode |
N02AX11
|
| gptkbp:CASNumber |
1204360-12-4
|
| gptkbp:chemicalFormula |
C22H30N2O5S
|
| gptkbp:contraindication |
known or suspected gastrointestinal obstruction
acute or severe bronchial asthma significant respiratory depression |
| gptkbp:controlledSubstanceSchedule |
gptkb:Schedule_II_(US)
|
| gptkbp:drugClass |
opioid agonist
|
| gptkbp:FDAApproved |
2020
|
| gptkbp:genericName |
oliceridine
|
| gptkbp:hasBoxedWarning |
addiction, abuse, and misuse
life-threatening respiratory depression neonatal opioid withdrawal syndrome risks from concomitant use with benzodiazepines or other CNS depressants |
| https://www.w3.org/2000/01/rdf-schema#label |
Olinvyk
|
| gptkbp:indication |
pain severe enough to require an opioid analgesic
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
Trevena Inc.
|
| gptkbp:mechanismOfAction |
mu-opioid receptor agonist
|
| gptkbp:molecularWeight |
434.55 g/mol
|
| gptkbp:pregnancyCategory |
Not recommended
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
vomiting constipation dizziness headache respiratory depression |
| gptkbp:usedFor |
management of acute pain
|
| gptkbp:bfsParent |
gptkb:Trevena
|
| gptkbp:bfsLayer |
7
|